Advanced search
Publication Cover
HIV Clinical Trials Volume 17, 2016 - Issue 2
Submit an article Journal homepage
293
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

Isabelle Poizot-MartinAix-Marseille University, AP-HM Sainte-Marguerite, Service d’Immuno-Hématologie Clinique, Marseille, France;INSERM, UMR 912 (SESSTIM), Marseille, FranceCorrespondence[email protected]
,
Eric BellissantRennes 1 University, Pontchaillou University Hospital, Service de Pharmacologie, Rennes, France;INSERM, CIC 1414 Clinical Investigation Centre, Rennes, France
,
Rodolphe GarraffoNice University, Pasteur University Hospital, Laboratoire de Pharmacologie et de Toxicologie Médicale, Nice, France
,
Philippe ColsonAix-Marseille University, AP-HM Timone, Fédération de Microbiologie Hospitalière, Marseille, France;URMITE, UM63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France
,
Lionel PirothBourgogne University, Bocage University Hospital, Département d’Infectiologie, UMR 1347, Dijon, France
,
Caroline SolasAix-Marseille University, AP-HM Timone, Service de Pharmacocinétique et Toxicologie, Marseille, France;INSERM, UMR 911 (CRO2), Marseille, France
,
Alain RenaultRennes 1 University, Pontchaillou University Hospital, Service de Pharmacologie, Rennes, France;INSERM, CIC 1414 Clinical Investigation Centre, Rennes, France
,
Marc BourlièreAP-HM Saint-Joseph, Service d’Hépato-Gastro-Entérologie, Marseille, France
,
Philippe HalfonEuropean Hospital, Marseille, France
,
Jade GhosnParis Descartes University, PRES Sorbonne Paris-Cité, EA 7327, Paris, France;Paris-Sud University, AP-HP Bicêtre Hospital, Service de Médecine Interne, Le Kremlin-Bicêtre, France
,
Laurent AlricToulouse 3 University, Purpan University Hospital, Service de Médecine Interne, Toulouse, France
,
Alissa NaqviNice University, Archet University Hospital, Service d’Infectiologie, Nice, France
,
Patrizia CarrieriINSERM, UMR 912 (SESSTIM), Marseille, France;ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d’Azur, Marseille, France
,
Jean-Michel MolinaParis 7 - Denis Diderot University, AP-HP Saint-Louis Hospital, Service des Maladies Infectieuses et Tropicales, Paris, France
& for the ANRS HC27 BOCEPREVIH Study Group show all
Pages 63-71 | Published online: 11 Feb 2016

References

  • Lacombe K. Hepatitis C, from screening to treatment, a revolution. J Int AIDS Soc. 2014;17:19499.
  • Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. Mar 2012;56:718–726.
  • Colson P, Purgus R, Borentain P, Gérolami R. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors. J Clin Virol. 2012;53:178–180.10.1016/j.jcv.2011.10.005
  • Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.10.1038/nature08309
  • Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011;49:1853–1860.10.1128/JCM.02139-10
  • Stanke-Labesque F, Loustaud-Ratti V, Babany G, Gagnieu MC, Marquet P. Ribavirin therapeutic drug monitoring: why, when and how? Fundam Clin Pharmacol. 2010;24:401–406.
  • Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology. 2007;46:971–981.
  • McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593.10.1056/NEJMoa0808010
  • de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Lack of a clinically significant drug–drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013;56:300–306.10.1093/cid/cis824
  • Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.10.1056/NEJMoa1009482
  • Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597–605.
  • Mandorfer M, Steiner S, Schwabl P, et al. Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: The HIVCOBOC-RGT study. J Infect Dis. 2015;211:729–73510.1093/infdis/jiu516
  • Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012;19:1–26.10.1111/jvh.2012.19.issue-s2
  • Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol. 2013;59:434–441.10.1016/j.jhep.2013.04.035
  • Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutierrez T, Mendez-Sanchez N, Uribe M, Chavez-Tapia NC. Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Ann Hepatol. 2015;14:46–57.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.